investor consid report singl factor make invest decis
revenu million
nexeon medsystem inc headquart dalla tx global medic devic compani primarili focus provid viant deep brain stimul product
improv qualiti life patient suffer neurolog diseas
maintain specul buy rate price target per share
nexeon medsystem substanti growth potenti viant deep brain stimul db product
consult firm crystal market research project global db market reach billion
approxim million due primarili increas number peopl diagnos
parkinson diseas increas awar neurolog disord
key advantag viant db system lie abil record bodi react neurostimul
provid doctor data patient respond therapi provid
increas revenu forecast million million due compani belief base
fda meet submit fda pre-market approv applic without clinic studi
eighteen month ahead schedul partli offset quicker anticip us launch slight
delay file ce mark europ expect product launch
compani report may net loss per share sale
million project loss million per share sale million
project loss per share sale million previous forecast loss
per share sale million sale forecast primarili reflect medi-lin oper
approxim million contribut devic sale research purpos project sg expens
million build sale forc infrastructur support launch viant system
project loss per share sale million prior loss per share
sale million sale forecast reflect revenu launch viant medi-lin
sale anticip compani rais equiti capit total approxim million
pleas view disclosur page
fda
determin
maintain nexeon medsystem inc specul buy rate price target
rate reflect european regul expect grant
viant approv file ce mark
earli compani complet pre-submiss
meet
scope
requir approv viant system base
meet compani believ submit fda
studi least eighteen month ahead schedul
septemb acquisit medi-lin contribut revenu approxim million
well provid support necessari launch nexeon viant deep brain stimul db system
approv receiv seven-month end march medi-lin gener revenu million
major gener establish multi-n account includ ge heathcar ethicon
johnson johnson compani revenu oper medic devic expertis medi-lin unit
assist nexeon achiev market share penetr ramp anticip nexeon viant system within
deep brain stimul market see chart estim compani could achiev least
global market share revenu million within estim billion db market estim
revenu primarili compris european us sale latter commenc earli pend pma
approv fda
price target approxim per share reflect potenti sale nexeon viant
deep brain stimul system discount year-ahead valu estim sale per share approxim
base approxim million share outstand unchang devic sale million see
chart share count estim includ current outstand warrant option approxim
million combin exercis issuanc million common share accord
thomson reuter three primari neurostimul devic compani abbot
lab owner st jude medic averag forward price-to-sal multipl prior
appli multipl unchang sale per share forecast discount factor
account execut regulatori risk obtain year-ahead valu approxim per share
nexeon medsystem inc valuat like remain restrain somewhat illiquid averag daili volum
three-month period end june approxim share compani receiv european
approv viant db system compani estim approv launch could occur earli
respect
view nexeon medsystem inc suitabl high-risk toler investor seek
exposur microcap medic devic compani high growth potenti
nexeon medsystem inc headquart dalla texa neuromodul medic devic manufactur
compani focus develop commerci viant deep brain stimul db product
product base nexeon neurostimul technolog platform treatment parkinson
associ diseas europ us via electr stimul tissu associ nervou system
medsystem belgium sprl owner oper medi-lin pulsu medic llc compani
oper puerto rico focus advanc comput biolog deep learn util associ
internet medic thing technolog pulsu medic llc asset focus research
develop cardiovascular diseas technolog
compani anticip viant continu meet critic mileston compani
complet iso certif process pivot hurdl prior regulatori submiss ce
mark author europ design verif process valid test requir
complet lead technic file complet submit regul part
technic file submit longer durat biocompat shelf life test
compani incorpor decemb februari nexeon surviv entiti follow
merger nexeon medsystem inc delawar corpor close nexeon medsystem issu
outstand prefer share convert million share compani restrict common stock
compani ipo june septemb commenc trade over-the-counter market
symbol nxnn
compani aim develop neurostimul technolog platform provid innov capabl
market physician patient improv solut tailor treatment option platform
fundament design viant db well develop futur product
neurostimul system use restor neuron equival neuron consist cell bodi
contain nucleu receiv incom nerv impuls axon carri impuls away cell
bodi function neurostimul platform act like brain pacemak send electr puls specif
target locat brain compani believ incorpor patient specif stimul program
provid advantag system approv sale europ
nexeon medsystem technolog platform compris thin implant puls gener two connector
electrod lead contact total brain implant puls gener custom chip
design deliv current multipl contact independ simultan technolog provid
broad rang frequenc puls width key platform advanc sens capabl provid
abil captur biopotenti defin electr potenti measur point live cell
tissu organ accompani biochem process monitor physiolog respons
stimul support research toward develop optim adapt closed-loop deep brain
stimul record signal process devic stream subsequ storag analysi
technolog enabl custom programm physician easili configur therapi maxim
clinic effici well document feedback patient
use compani technolog platform design viant db devic deliv effect therapeut result
faster sustain result longer viant deliv multipl current sourc stimul combin sens
capabl singl recharg devic devic recharg skin implant on-
board sens capabl develop provid clinician abil measur analyz brain
activ adjac db lead quickli confid locat best locat stimul matter
minut rather hour system market use trial-and-error program scheme sens
capabl design enabl clinician research captur stream brain record extern
devic subsequ analysi physician updat softwar viant system without need
compani aim complet develop viant db system well submit regulatori author
europ us respect compani also invest complet develop
build manufactur capac necessari support approv commerci launch viant db
addit nexeon partner contract manufactur util manufactur capabl
order achiev oper effici upon complet viant db system data dossier compani
submit pre-market approv european author order obtain ce mark compani anticip
european ce mark approv commerci launch major european market us launch expect
occur earli
compani began build sale market organ process includ build
intern sale organ combin distributor independ sale agent limit number
direct employe anticip launch major european market compani sale organ
target movement disord specialist locat primarili larg academ center well refer
network neurologist countri exist reimburs coverag db therapi
compani intend grow oper subsequ regulatori approv viant db system
research develop preclin clinic level order add capabl db devic
end compani commenc enrol clinic studi patient explor
transcutan measur across depth skin auricular vagu nerv stimul avn allevi atrial
fibril irregular rapid heart rate addit near term innov like come advanc
compani work maxim synergi medic devic manufactur medi-lin
expertis experi manufactur suppli chain manag qualiti system control necessari
reduc risk lead commerci launch viant db system medi-lin also assist
develop follow-on product need make technolog advanc
solidifi technolog nexeon possess patent portfolio product develop ensur
abil oper critic success commerci compani platform futur
compani attempt focu internet medic thing enabl nexeon util issu pend
patent maximum commerci benefit growth
compani asset futur develop one asset micro-perfor cathet balloon mpcb
novel balloon materi util carbon nanotub polym balloon materi protect
approxim patent contain wholli own subsidiari pulsu medic llc
compani first launch viant db system europ like receiv european approv
ce mark certif mark indic conform health safeti environment protect standard
product sold within european econom area
european launch strategi highli focus led nexeon presid brian blischak vice-president sale
market daniel powel compani reli experi expertis relationship
built within neurostimul market lead mix direct sale profession distributor market
nexeon viant db system approxim key opinion leader european market
team task market nexon advanc viant db system key opinion leader europ
shown willing past switch technolog technolog advanc occur histori
deep brain stimul market europ indic technolog flip occur enter
europ advanc product compar market leader time compani seek
replic flip util custom input custom design review understand key option leader
seek newli advanc product well support clinic workflow need sens
technolog attach viant db
present compani estim base reason assumpt
product encourag
launch europ see chart right european sale goal compani aim establish posit
european db market creat platform
call neural hub success establish
neural hub platform could becom valuabl
tool creat intellig network
identifi effect outcom patient use
compani nerostimul system order
particip physician util
compani system provid outcom data
neural hub allow target
potenti better patient outcom futur
accord ibisworld medic devic essenti
healthcar product manufactur gener
technolog advanc legisl expans
healthcar access improv economi
stimul demand medic devic five year
support futur growth age us
popul contribut high incid
ibisworld estim us neuromodul spinal devis revenu reach billion
estim billion forecast assum segment remain see chart
right neuromodul devic design treatment pain urolog gastroenterolog
disord movement disord psycholog disord growth neuromodul segment
driven potenti allevi mani debilit condit neural pathway play role includ
chronic pain parkinson diseas essenti tremor dystonia epilepsi gastroparesi hear loss major
treatment-resist depress obsessive-compuls disord urinari incontin
februari reportlink com publish report global medic devic technolog market indic
market project reach billion billion averag annual
growth global growth medic devic market support rise adopt
advanc technolog manufactur medic devic
decemb marketresearchstor com publish deep brain stimul devic market report
estim deep brain stimul devic market reach million million
market anticip grow annual reach least million largest compani
fuel market growth includ boston scientif st jude medic part abbott
consult firm crystal market research project global deep brain stimul db market reach
billion estim million due primarili increas number peopl
diagnos parkinson diseas well increas awar neurolog disord growth db
market reflect rise number peopl suffer parkinson diseas increas awar
march global market insight inc anticip global neurostimul devic market grow annual
billion billion global neurostimul devic market experienc
signific growth due primarili increas preval chronic pain rise incid neurolog
diseas overal market benefit grow elderli popul increas invest research
develop innov neurostimul devic us censu bureau project year
period world see number peopl increas million overal elderli
popul nearli doubl billion global compar gener popul growth
futur european growth neurostimul devic market support initi taken variou
govern improv healthcar facil region well increas incid chronic pain
neurolog diseas accord world organ neurolog disord affect one-third
popul europ everi year
estim deep brain stimul therapi use world-wide patient treat chronic
neurolog diseas year fda approv certain db devic treatment parkinson
diseas essenti tremor affect approxim seven million eight million peopl unit state
respect db investig therapi neurolog disord epilepsi treatment-resist
major depress alzheim diseas
basi forecast
forecast reflect oper belgium base medi-lin acquir septemb medi-lin
corpor histori provid engin manufactur medic devic medic
laboratori pharmaceut industri subsidiari manufactur radio-pharmaci urolog product
provid world-wide product medic devic custom countri suppli chain capabl
product custom custom field urolog implant neurosurgeri intervent
cathet well micro-thin cuff cathet seven-month period end march medi-lin
subsidiari gener revenu million
forecast includ approxim million contribut devic sale research purpos
includ commerci sale nexeon viant db howev european approv like occur
decemb includ nearli million neurostimul revenu forecast
forecast compani record incom tax forecast period march compani
nearli million net oper loss carryov begin expir
project revenu million prior million increas revenu forecast reflect
result approxim million non-commerci devic sale research purpos
project gross profit million reflect gross margin approxim oper loss
approxim million compar million forecast oper expens margin
anticip increas oper expens million due primarili
increas sg expens million reflect septemb acquisit medi-lin well
build sale market infrastructur start support launch viant db system
project increas expens million declin expens million
anticip non-oper expens consist exclus interest expens compar non-
oper incom million includ million gain purchas asset
interest expens relat parti increas interest expens due compani outstand
debt excess million year compar four month
project net loss million per share previous project net loss million
per share revenu million forecast base averag share count million
compar million
project revenu million prior million medi-lin sale nearli million flat
compar forecast neurostimul sale approach million neurostimul sale
reflect launch compani viant db system europ
project increas gross profit million reflect gross margin approxim
compar gross margin improv occur due forecast includ higher margin
viant db system sale oper loss increas million due increas
oper expens margin anticip increas oper expens
million due primarili increas sg expens million support on-going effort
launch viant db europ fda submiss get system approv us end
project increas expens million flat expens million
anticip non-oper expens consist exclus interest expens flat interest expens
reflect higher interest rate off-set lower outstand debt
project net loss million per share averag share count million compar
estim million previous project net loss million per share
project cash burn million increas work capit grant advanc
common stock offer estim million cover cash use oper million capit
expenditur project cash increas million million decemb
project cash burn million increas work capit grant advanc
estim million common stock offer cover cash use oper million capit
expenditur project cash increas million decemb
estim compani need complet capit rais end due burn rate order
maintain oper growth compani may addit financi flexibl due receipt
approxim million new research develop grant award compani puerto rican
subsidiari receiv approv govern econom incent develop puerto rico act
fix incom tax rate tax credit research develop nexeon option sell
 tax credit third parti
nexeon medsystem two busi segment within medic devic industri manufactur
neurostimul manufactur oper conduct medi-lin subsidiari belgium
produc singl use medic devic medic pharmaceut custom neurostimul oper includ
develop manufactur commerci compani neurostimul technolog
treatment variou neurolog disord electr stimul neural tissu compani first
commerci applic platform viant deep brain stimul segment
oper us puerto rico belgium germani
total revenu increas million year-ago period increas reflect million
manufactur sale august acquisit medi-lin neurostimul devic sale
revenu stem singl custom purchas pre-clin use compani
sale compar due primarili belgian govern credit employ staff
research develop
gross profit million compar gross margin million cost revenu reflect
manufactur activ stem august acquisit medi-lin well product
devic sale custom pre-clin use
oper expens consist sg depreci amort cost increas million
million year-ago period
sg expens increas reflect cost associ medi-lin subsidiari partli off-set
reduct capit format investor relat cost depreci amort cost increas
due acquisit cardiovascular diseas technolog patent expens decreas
due increas applic grant relat activ record reduct research
develop expens off-set parti research develop activ medi-lin subsidiari
non-oper incom compar expens year-ago period current period
interest expens compar interest expens year-ago period compani record
expens relat loss stock exchang interest incom relat parti net loss
per share compar net loss million per share
compani million averag share compar million share year-ago period project net
loss million per share revenu million million averag share
cash burn increas work capit result cash use oper
increas work capit due primarili advanc grant payment proce borrow
cover cash use oper capit expenditur decreas march
march compani total debt million million long-term compris primarili
senior convert secur note matur million secur bank loan
matur secur bank loan matur loan subsidi matur
revolv credit facil bb apr outstand revolv
credit card comerica bank outstand line credit cbc banqu interest rate
euro libor
convert note senior secur oblig nexeon medsystem inc prioriti futur
indebted note holder leonit capit right time convert part
outstand unpaid princip amount accru unpaid interest note compani issu two-year
five-year warrant share compani common stock period
februari medi-lin line credit cbc banqu amend increas advanc amount
approxim structur straight loan interest rate euribor rate
period fund drawn secur loan includ pledg medi-lin busi asset
march outstand balanc approxim avail drawdown
april point facil reduc approxim reduc
approxim may
compani expect financ cash need combin debt equiti financ well
expect non-dilut research grant award compani commit extern sourc fund
beyond grant
neuromodul process nervou activ regul way control physiolog
level sever class neurotransmitt industri character rapidli evolv technolog intens
competit numer compani work technolog advanc applic current devic
within neuromodul market competit factor industri includ product reliabl perform
technolog qualiti servic custom support price reimburs approv health care insur
provid compani industri also face competit market distribut collabor
develop agreement establish relationship academ research institut licens
compani compet sale neuromodul product global includ publicli trade boston
scientif abbott laboratori acquisit st jude medic nevro compani well privat
compani pin medic aleva neurotherapeut compani nexeon compet
significantli greater financi technic market resourc competit also includ academ institut
govern agenc public privat research organ develop project altern
therapi devic drug could competit environ
view princip risk underli stock
nexeon medsystem inc yet turn profit march compani accumul deficit reach
nearli million million loss like continu substanti forecast
period lack profit could result compani inabl execut growth strategi and/or seek
dilut financ factor rais substanti doubt compani auditor abil continu
nexeon medsystem need addit capit order execut busi plan sinc month
capit oper two segment compani financ oper march privat
placement nation institut award research develop project loan
compani largest sharehold rosellini scientif therefor compani depend upon addit
capit form debt equiti and/or scientif grant loan order continu oper commerci
product present time compani arrang fulli fund capit
requir compani unabl obtain capit requir fund oper order reach
profit oper may need modifi curtail
compani abl secur capit sale convert debt equiti secur ownership
interest stockhold may dilut term secur issu may includ liquid
prefer advers affect right common stockhold
nexeon medsystem inc own us foreign patent patent applic reflect intellectu properti
underli intravascular drug deliveri system technolog platform major patent expir
compani also acquir non-exclus licens portfolio patent
subject royalti compani growth depend monet patent expir
compani aim make intellectu properti acquisit enhanc product develop activ
inabl integr intellectu properti acquisit could neg advers impact compani abil
pursuant merger compani pay royalti limit liabil compani former
nxde sharehold member net product sale deriv compani affili license
commerci patent compani portfolio march sale gener
subject royalti oblig
compani unabl obtain reimburs code success develop approv devic
treatment would like lead slower anticip adopt rate howev compani believ
approv use devic treatment fall current reimburs standard although
compani manag team skill obtain devic reimburs assur
neurostimul devic approv reimburs would advers affect devic adopt
compani like sell medic devic treatment custom locat outsid us
oper subject legal polit regulatori social requir econom condit
jurisdict conduct compani unabl follow regul adapt condit
individu countri outsid us growth prospect may restrain
physician like adopt compani devic determin clinic data publish peer review
journal articl indic would favor altern convent treatment howev physician
tend slow come chang due perceiv liabil risk gener associ use new
devic limit avail reimburs third parti payer even data favor
offic director nexeon medsystem inc control interest approxim
outstand vote stock april one sharehold william rosellini compani founder ceo own
control interest nearli outstand vote stock could potenti influenc
outcom matter requir stockhold approv decis may may best interest
sharehold
compani financi result equiti valu subject risk uncertainti includ competit
oper financi market regulatori risk and/or event risk may caus actual result differ
three-month period end june averag daili volum approxim compani
float million share share outstand million
thousand
incept decemb decemb
compani report taglich brother estim
thousand
incept decemb decemb
compani report taglich brother estim
thousand
compani report taglich brother estim
thousand
compani report taglich brother estim
invest bank servic compani cover past month
